<!DOCTYPE html>
<!-- paulirish.com/2008/conditional-stylesheets-vs-css-hacks-answer-neither/
-->
<!--[if lt IE 7]>
<html class="no-js lt-ie9 lt-ie8 lt-ie7" lang="en">
<![endif]-->
<!--[if IE 7]>
<html class="no-js lt-ie9 lt-ie8" lang="en">
<![endif]-->
<!--[if IE 8]>
<html class="no-js lt-ie9" lang="en">
<![endif]-->
<!--[if gt IE 8]>
<!-->
<html class="no-js" lang="en">
<!--<![endif]-->

<head>
    <meta charset="utf-8" />
    <!-- Set the viewport width to device width for mobile -->
    <meta name="viewport" content="width=device-width" />
    <title>
        PracticeUpdate : Expert Opinion Item
    </title>
    <link rel="stylesheet" href="assets/css/app.css">
    <link rel="stylesheet" href="assets/css/font-awesome.css">
    <link rel="stylesheet" href="assets/css/fc-webicons.css">
    <link rel="stylesheet" href="assets/css/foundation-icons-general.css">
    <script src="assets/js/foundation/modernizr.foundation.js">
    </script>
    <!-- IE Fix for HTML5 Tags -->
    <!--[if lt IE 9]>
        <script src="http://html5shiv.googlecode.com/svn/trunk/html5.js">
        </script>
    <![endif]-->
</head>

<body id="page" class="update off-canvas slide-nav expert-opinion-item logged-out">
    <div class="widget ad">
        <div id="leaderboard" class="Breast ad-container">
            <div class="ad-title">
                <span class="ad-title-text">
                    advertisement
                </span>
            </div>
            <!--/.ad-title-->
            <div id="leaderboardcontent" class="ad-content">
            </div>
            <!--.ad-content-->
        </div>
        <!--/#leaderboard.ad-container-->
    </div>
    <!--/.widget.ad-->
    <div class="page-header">
    </div>
    <!--/.page-header-->
    <div class="page-content">
        <section role="main">
            <div class="single-item-container">
                <article class="type-expert-opinion single-item">
                    <!-- info taken from: http://oncologystat.com/viewpoints/seminal_articles/Seminal_Articles_Germ_Cell_Tumors.html
                    -->
                    <div class="item-header-container">
                        <header class="item-header">
                            <div class="flag-container">
                                <span class="flag featured">
                                    <i class="icon-bolt">
                                    </i>
                                    featured
                                </span>
                                <span class="flag story-of-the-week">
                                    <i class="icon-bolt">
                                    </i>
                                    story of the week
                                </span>
                            </div>
                            <div class="meta pub-meta">
                                <span class="item-type">
                                    Seminal Article
                                </span>
                                <span class="item-pub-date">
                                    <time datetime="12-12-19">
                                        December 19, 2012
                                </span>
                            </div>
                            <hgroup class="item-title-container">
                                <h1 class="item-title">
                                    Seminal Articlesâ€”CNS and Brain Malignancies
                                </h1>
                                <p class="item-citation">
                                    <!-- {{source.citation}} -->
                                    2012 Mar 12, Roger Stupp, MD, Editor: Patrick Morris, MD
                                </p>
                            </hgroup>
                            <!-- /.item-title-container -->
                        </header>
                    </div>
                    <!--/.item-header-container-->
                    <div class="item-content-container">
                        <div class="item-content">
                            <div class="item-content-section">
                                <section class="seminal-article-body">
                                    <div class="seminal-article-body-container">
                                        <div class="source-container">
                                            <div class="vcard">
                                            </div>
                                            <!--/.vcard-->
                                        </div>
                                        <!--/.source-container-->
                                        <p>Based on our expert's review, here are the must-read articles for every oncologist
										  about CNS and brain malignancies.</p>

										  <p><strong>Glioma</strong></p>

											  <p><strong>Background and Reviews</strong></p>

										  <p>1. Pignatti F, van den Bent M, Curran D, et al; European Organization for Research
										  and Treatment of Cancer Brain Tumor Cooperative Group; European Organization for
										  Research and Treatment of Cancer Radiotherapy Cooperative Group. Prognostic factors for
										  survival in adult patients with cerebral low-grade glioma. <a target="_blank" href=
										  "http://jco.ascopubs.org/content/20/8/2076.full.pdf+html">J Clin Oncol. 2002 Apr
										  15;20(8):2076-2084</a>.</p>

										  <p>2. Stummer W, Reulen HJ, Meinel T, et al; ALA-Glioma Study Group. Extent of
										  resection and survival in glioblastoma multiforme: identification of and adjustment for
										  bias. <a target="_blank" href=
										  "http://journals.lww.com/neurosurgery/Fulltext/2008/03000/Extent_of_Resection_and_Survival_in_Glioblastoma.3.aspx">
										  Neurosurgery. 2008 Mar;62(3):564-576</a>.</p>

										  <p>3. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for
										  high-grade gliomas: response assessment in neuro-oncology working group. <a target=
										  "_blank" href="http://jco.ascopubs.org/content/28/11/1963.long">J Clin Oncol. 2010 Apr
										  10;28(11):1963-1972</a>.</p>

										  <p>4. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for
										  phase II studies of supratentorial malignant glioma. <a target="_blank" href=
										  "http://jco.ascopubs.org/content/8/7/1277.long">J Clin Oncol. 1990
										  Jul;8(7):1277-1280</a>.</p>

										  <p>5. Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant
										  glioma: standard of care and future directions. <a target="_blank" href=
										  "http://jco.ascopubs.org/content/25/26/4127.long">J Clin Oncol. 2007 Sep
										  10;25(26):4127-4136</a>.</p>

										  <p>6. Weller M, Stupp R, Reifenberger G, et al. MGMT promoter methylation in malignant
										  gliomas: ready for personalized medicine? <a target="_blank" href=
										  "http://www.nature.com/nrneurol/journal/v6/n1/full/nrneurol.2009.197.html">Nat Rev
										  Neurol. 2010 Jan;6(1):39-51</a>.</p>

											  <p><strong>Radiotherapy</strong></p>

										  <p>7. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in
										  radiation therapy of low-grade cerebral glioma: European Organization for Research and
										  Treatment of Cancer (EORTC) Study 22844. <a target="_blank" href=
										  "http://www.sciencedirect.com/science/article/pii/S0360301696003525">Int J Radiat Oncol
										  Biol Phys. 1996 Oct 1;36(3):549-556</a>. Elsevier</p>

										  <p>8. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low-
										  versus high-dose radiation therapy in adults with supratentorial low-grade glioma:
										  initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
										  Group/Eastern Cooperative Oncology Group study. <a target="_blank" href=
										  "http://jco.ascopubs.org/content/20/9/2267.long">J Clin Oncol. 2002 May
										  1;20(9):2267-2276</a>.</p>

										  <p>9. van den Bent MJ, Afra D, de Witte O, et al; EORTC Radiotherapy and Brain Tumor
										  Groups and the UK Medical Research Council. Long-term efficacy of early versus delayed
										  radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845
										  randomised trial. <a target="_blank" href=
										  "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2805%2967070-5/fulltext">
										  Lancet. 2005 Sep 17-23;366(9490):985-990</a>.<br />
										  <strong><br />
										  Chemotherapy</strong></p>
											  <p><strong>PCV</strong></p>

										  <p>10. Levin VA, Wara WM, Davis RL,et al. Phase III comparison of BCNU and the
										  combination of procarbazine, CCNU, and vincristine administered after radiotherapy with
										  hydroxyurea for malignant gliomas. <a target="_blank" href=
										  "http://thejns.org/doi/abs/10.3171/jns.1985.63.2.0218?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%3dpubmed">
										  J Neurosurg. 1985 Aug;63(2):218-223</a>.</p>

										  <p>11. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus
										  radiotherapy compared with radiotherapy alone for pure and mixed anaplastic
										  oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. <a target=
										  "_blank" href="http://jco.ascopubs.org/content/24/18/2707.long">J Clin Oncol. 2006 Jun
										  20;24(18):2707-2714</a>.</p>

										  <p>12. van den Bent MJ, Carpentier AF, Brandes AA,et al. Adjuvant procarbazine,
										  lomustine, and vincristine improves progression-free survival but not overall survival
										  in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized
										  European Organisation for Research and Treatment of Cancer phase III trial. <a target=
										  "_blank" href="http://jco.ascopubs.org/content/24/18/2715.long">J Clin Oncol. 2006 Jun
										  20;24(18):2715-2722</a>.</p>
											  <p><strong>Temozolomide</strong></p>

										  <p>13. Yung WK, Prados MD, Yaya-Tur R,et al. Multicenter phase II trial of temozolomide
										  in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first
										  relapse. Temodal Brain Tumor Group. <a target="_blank" href=
										  "http://jco.ascopubs.org/content/17/9/2762.long">J Clin Oncol. 1999
										  Sep;17(9):2762-2771</a>.</p>

										  <p>14. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for
										  patients with newly diagnosed glioblastoma multiforme treated with concomitant
										  radiation plus temozolomide followed by adjuvant temozolomide. <a target="_blank" href=
										  "http://jco.ascopubs.org/content/20/5/1375.long">J Clin Oncol. 2002 Mar
										  1;20(5):1375-1382</a>.</p>

										  <p>15. Stupp R, Mason WP, van den Bent MJ, et al; European Organisation for Research
										  and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute
										  of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant
										  temozolomide for glioblastoma. <a target="_blank" href=
										  "http://www.nejm.org/doi/full/10.1056/NEJMoa043330">N Engl J Med. 2005 Mar
										  10;352(10):987-996</a>. <strong>Free</strong></p>

										  <p>16. Stupp R, Hegi ME, Mason WP, et al; European Organisation for Research and
										  Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer
										  Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and
										  adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a
										  randomised phase III study: 5-year analysis of the EORTC-NCIC trial. <a target="_blank"
										  href="http://www.sciencedirect.com/science/article/pii/S1470204509700257">Lancet Oncol.
										  2009 May;10(5):459-466</a>. Elsevier</p>

										  <p>17. Gilbert MR, Wang M, Aldape KD, et al. RTOG 0525: A randomized phase III trial
										  comparing standard adjuvant temozolomide with a dose-dense schedule in newly diagnosed
										  glioblastoma. Presented at: 2011 ASCO Annual Meeting; June 3-7, 2011; Chicago, IL.
										  Abstract 2006. <a target="_blank" href=
										  "http://www.asco.org/ascov2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=102&amp;abstractID=79659">
										  J Clin Oncol. 2011;29(suppl;abstr 2006)</a>.</p>

											  <p><strong>Bevacizumab and Antiangiongenic Agents</strong></p>

										  <p>18. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab
										  and irinotecan in recurrent malignant glioma. <a target="_blank" href=
										  "http://clincancerres.aacrjournals.org/content/13/4/1253.long">Clin Cancer Res. 2007
										  Feb 15;13(4):1253-1259</a>. <strong>Free</strong></p>

										  <p>19. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab
										  followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
										  <a target="_blank" href=
										  "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2645088/?tool=pubmed">J Clin Oncol. 2009
										  Feb 10;27(5):740-745</a>. <strong>Free</strong></p>

										  <p>20. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with
										  irinotecan in recurrent glioblastoma. <a target="_blank" href=
										  "http://jco.ascopubs.org/content/27/28/4733.long">J Clin Oncol. 2009 Oct
										  1;27(28):4733-4740</a>.</p>

										  <p>21. Lai A, Tran A, Nghiemphu PL, et al.. Phase II study of bevacizumab plus
										  temozolomide during and after radiation therapy for patients with newly diagnosed
										  glioblastoma multiforme. <a target="_blank" href=
										  "http://jco.ascopubs.org/content/early/2010/12/02/JCO.2010.30.2729.full.pdf+html">J
										  Clin Oncol. 2011 Jan 10;29(2):142-148</a>.</p>

										  <p>22. Wick W, Weller M, van den Bent M, Stupp R. Bevacizumab and recurrent malignant
										  gliomas: a European perspective. <a target="_blank" href=
										  "http://jco.ascopubs.org/content/28/12/e188.long">J Clin Oncol. 2010 Apr
										  20;28(12):e188-189; author reply e190-192</a>.</p>

										  <p>23. Batchelor TT, Sorensen AG, di Tomaso E,et al. AZD2171, a pan-VEGF receptor
										  tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in
										  glioblastoma patients. <a target="_blank" href=
										  "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2748664/?tool=pubmed">Cancer Cell. 2007
										  Jan;11(1):83-95</a>. <strong>Free</strong></p>

										  <p>24. Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and
										  temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide
										  maintenance therapy in patients with newly diagnosed glioblastoma. <a target="_blank"
										  href="http://jco.ascopubs.org/content/28/16/2712.long">J Clin Oncol. 2010 Jun
										  1;28(16):2712-2718</a>.</p>

											  <p><strong>Biology and Molecular Markers</strong></p>

										  <p>25. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of
										  chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
										  <a target="_blank" href="http://jnci.oxfordjournals.org/content/90/19/1473.long">J Natl
										  Cancer Inst. 1998 Oct 7;90(19):1473-1479</a>. <strong>Free</strong></p>

										  <p>26. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined
										  deletions of 1p and 19q and predicts a better prognosis of patients with
										  oligodendroglioma. <a target="_blank" href=
										  "http://cancerres.aacrjournals.org/content/66/20/9852.long">Cancer Res. 2006 Oct
										  15;66(20):9852-9861</a>. <strong>Free</strong></p>

										  <p>27. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair
										  gene MGMT and the clinical response of gliomas to alkylating agents. <a target="_blank"
										  href="http://www.nejm.org/doi/full/10.1056/NEJM200011093431901">N Engl J Med. 2000 Nov
										  9;343(19):1350-1354. Erratum in: N Engl J Med 2000 Dec 7;343(23):1740</a>.
										  <strong>Free</strong></p>

										  <p>28. Hegi ME, Diserens AC, Gorlia T,et al. MGMT gene silencing and benefit from
										  temozolomide in glioblastoma. <a target="_blank" href=
										  "http://www.nejm.org/doi/full/10.1056/NEJMoa043331">N Engl J Med. 2005 Mar
										  10;352(10):997-1003</a>. <strong>Free</strong></p>

										  <p>29. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. <a target=
										  "_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa0808710">N Engl J Med. 2009
										  Feb 19;360(8):765-773</a>.</p>

										  <p>30. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation
										  is an important prognostic biomarker in gliomas. <a target="_blank" href=
										  "http://jco.ascopubs.org/content/27/25/4150.long">J Clin Oncol. 2009 Sep
										  1;27(25):4150-4154</a>.</p>

										  <p><strong>Primary CNS Lymphoma</strong></p>

											  <p><strong>Chemotherapy</strong></p>

										  <p>31. DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and
										  radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology
										  Group Study 93-10. <a target="_blank" href=
										  "http://jco.ascopubs.org/content/20/24/4643.long">J Clin Oncol. 2002 Dec
										  15;20(24):4643-4648</a>.</p>

										  <p>32. Batchelor T, Carson K, O'Neill A, et al: Treatment of primary CNS lymphoma with
										  methotrexate and deferred radiotherapy: a report of NABTT 96-07. <a target="_blank"
										  href="http://jco.ascopubs.org/content/21/6/1044.long">J Clin Oncol. 2003 March
										  15;21(6):1044-1049</a>.</p>

										  <p>33. Hoang-Xuan K, Taillandier L, Chinot O, et al: Chemotherapy alone as initial
										  treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase
										  II study (26952) of the European Organization for Research and Treatment of Cancer
										  Brain Tumor Group. <a target="_blank" href=
										  "http://jco.ascopubs.org/content/21/14/2726.long">J Clin Oncol. 2003 July
										  15;21(14):2726-2731</a>.</p>

										  <p>34. Abrey LE, Moskowitz CH, Mason WP, et al: Intensive methotrexate and cytarabine
										  followed by high-dose chemotherapy with autologous stem-cell rescue in patients with
										  newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. <a target="_blank"
										  href="http://jco.ascopubs.org/content/21/22/4151.long">J Clin Oncol. 2003
										  Nov15;21(22):4151-4156</a>.</p>

										  <p>35. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et al: High-dose
										  methotrexate-based chemotherapy followed by consolidating radiotherapy in
										  non-AIDS-related primary central nervous system lymphoma: European Organization for
										  Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. <a target=
										  "_blank" href="http://jco.ascopubs.org/content/21/24/4483.long">J Clin Oncol. 2003 Dec
										  15;21(24):4483-4488</a>.</p>

										  <p>36. Pels H, Schmidt-Wolf IG, Glasmacher A, et al. Primary central nervous system
										  lymphoma: results of a pilot and phase II study of systemic and intraventricular
										  chemotherapy with deferred radiotherapy. <a target="_blank" href=
										  "http://jco.ascopubs.org/content/21/24/4489.long">J Clin Oncol. 2003 Dec
										  15;21(24):4489-4495</a>.</p>

										  <p>37. Ferreri AJ, Dell'Oro S, Foppoli M, et al: MATILDE regimen followed by
										  radiotherapy is an active strategy against primary CNS lymphomas. <a target="_blank"
										  href="http://www.neurology.org/content/66/9/1435.abstract">Neurology. 2006 May
										  9;66(9):1435-1438</a>.</p>

										  <p>38. Shah GD, Yahalom J, Correa DD, et al: Combined immunochemotherapy with reduced
										  whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. <a target="_blank"
										  href="http://jco.ascopubs.org/content/25/30/4730.full.pdf">J Clin Oncol. 2007 Oct
										  20;25(30):4730-4735</a>.</p>

										  <p>39. Ferreri AJ, Reni M, Foppoli M, et al; International Extranodal Lymphoma Study
										  Group (IELSG). High-dose cytarabine plus high-dose methotrexate versus high-dose
										  methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
										  <a target="_blank" href=
										  "http://www.sciencedirect.com/science/article/pii/S0140673609614161">Lancet. 2009 Oct
										  31;374(9700):1512-1520</a>. Elsevier</p>

										  <p>40. Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole
										  brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised,
										  non-inferiority trial. <a target="_blank" href=
										  "http://www.sciencedirect.com/science/article/pii/S1470204510702291">Lancet Oncol. 2010
										  Nov;11(11):1036-1047</a>. Elsevier</p>
											  <p><strong>Stem Cell Transplant</strong></p>

										  <p>41. Cheng T, Forsyth P, Chaudhry A, et al: High-dose thiotepa, busulfan,
										  cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary
										  CNS lymphoma. <a target="_blank" href=
										  "http://www.nature.com/bmt/journal/v31/n8/pdf/1703917a.pdf">Bone Marrow Transplant.
										  2003;31:679-685</a>.</p>

										  <p>42. Brevet M, Garidi R, Gruson B, et al: First-line autologous stem cell
										  transplantation in primary CNS lymphoma. <a target="_blank" href=
										  "http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0609.2005.00508.x/pdf">Eur J
										  Haematol. 2005 Oct;75(4):288-292</a>.</p>

										  <p>43. Colombat P, Lemevel A, Bertrand P, et al: High-dose chemotherapy with autologous
										  stem cell transplantation as first-line therapy for primary CNS lymphoma in patients
										  younger than 60 years: a multicenter phase II study of the GOELAMS group. <a target=
										  "_blank" href="http://www.nature.com/bmt/journal/v38/n6/full/1705452a.html">Bone Marrow
										  Transplant. 2006;38:417-420</a>.</p>

										  <p>44. Illerhaus G, Marks R, Ihorst G, et al: High-dose chemotherapy with autologous
										  stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of
										  primary CNS lymphoma. <a target="_blank" href=
										  "http://jco.ascopubs.org/content/24/24/3865.long">J Clin Oncol. 2006 Aug
										  20;24(24):3865-3870</a>.</p>

										  <p>45. Montemurro M, Kiefer T, Schuler F, et al: Primary central nervous system
										  lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous
										  stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the
										  multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study.
										  <a target="_blank" href="http://annonc.oxfordjournals.org/content/18/4/665.long">Ann
										  Oncol. 2007 Apr 4;18(4):665-671</a>. <strong>Free</strong></p>

										  <p>46. Illerhaus G, Muller F, Feuerhake F, et al: High-dose chemotherapy and autologous
										  stem-cell transplantation without consolidating radiotherapy as first-line treatment
										  for primary lymphoma of the central nervous system. <a target="_blank" href=
										  "http://haematologica-thj.org/content/93/1/147.fulln">Haematologica. 2008 Jan
										  1;93(1):147-148</a>. <strong>Free</strong></p>

										  <p>47. Soussain C, Hoang-Xuan K, Taillandier L, et al: Intensive chemotherapy followed
										  by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and
										  intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie
										  Cellulaire. <a target="_blank" href="http://jco.ascopubs.org/content/26/15/2512.long">J
										  Clin Oncol. 2008 May 20;26(15):2512-2518</a>.</p>

											  <p><strong>Radiotherapy</strong></p>

										  <p>48. Nguyen PL, Chakravarti A, Finkelstein DM, et al: Results of whole-brain
										  radiation as salvage of methotrexate failure for immunocompetent patients with primary
										  CNS lymphoma. <a target="_blank" href=
										  "http://jco.ascopubs.org/content/23/7/1507.long">J Clin Oncol. 2005 March
										  1;23(7):1507-1513</a>.</p>

										  <p>49. Hottinger AF, DeAngelis LM, Yahalom J, et al: Salvage whole brain radiotherapy
										  for recurrent or refractory primary CNS lymphoma. <a target="_blank" href=
										  "http://www.ncbi.nlm.nih.gov/pubmed/17846417">Neurology. 2007 Sept
										  11;69(11):1178-1182</a>.</p>
                                    </div>
                                    <!--/.seminal-article-body-container -->
                                </section>
                                <!-- /.seminal-article-body -->
                            </div>
                            <!-- ./item-content-section -->
                        </div>
                        <!-- ./item-content -->
                    </div>
                    <!-- /.item-conten-container -->
                    <hr />
                    <footer class="copyright item-footer">
                        <img class="logo" src="content/img/feed/imng_logo.gif" alt="IMNG Medical Media"
                        />
                        <p>
                            Copyright &copy; 2012 Elsevier
                        </p>
                    </footer>
            </div>
            <!--/.item-container-->
            <div class="recommended">
                <div class="recent">
                </div>
                <!--/.recent-->
                <div class="ad">
                    <img src="http://placehold.it/300x250" align="ad" title="ad" />
                </div>
            </div>
            <!--/.recommended-->
        </section>
        <!--/[role="main"]-->
        <section id="sidebar" role="complementary">
            <div class="dashboard">
                <div class="panel cta register">
                    <p>
                        <!-- Meet Our Experts -->
                        Become a member to customize this page.
                        <p>
                            <a class="button" href="#action-register">Register for free</a>
                </div>
                <!--/.panel.cta.register-->
                <div class="component user-console">
                </div>
                <!--/.component.user-console-->
                <div class="component user-topic">
                </div>
                <!--/.component.user-topic-->
                <div class="component topic-spotlight">
                </div>
                <!--/.component.topic-spotlight-->
                <div class="panel">
                    <img src="http://placehold.it/200x200" />
                    <p>
                        <!-- Meet Our Experts -->
                        Meet our Advisory and Editorial Boards comprised of physician editors
                        and world-renowned experts.
                        <p>
                </div>
            </div>
            <!--/.sidebar-->
        </section>
        <!--/.[role="complimentary"]-->
    </div>
    <!--/.page-content-->
	<div class="page-footer-container">
    <footer class="page-footer">
    </footer>
	</div><!-- /.page-footer-container -->
    <!-- /.page-footer -->
    <!-- Included JS Files (Uncompressed) -->
    <script src="assets/js/foundation/jquery.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.accordion.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.alerts.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.buttons.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.forms.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.mediaQueryToggle.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.navigation.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.orbit.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.reveal.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.tabs.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.tooltips.js">
    </script>
    <script src="assets/js/foundation/jquery.placeholder.js">
    </script>
    <script src="assets/js/foundation/app.js">
    </script>
    <script src="assets/js/foundation/jquery.offcanvas.js">
    </script>
    <script src="assets/js/mustache.js">
    </script>
    <!-- Mustache - homepage feed template -->
    <script>
                    	<!--
	Mustache - homepage feed template -->
	$.getJSON('content/json/feed.json', function(data) {
	    $.get('assets/mustache/feed-item.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.stream-container').html(html);
	    });

	});

	<!--
	Mustache - homepage recent template -->
	$.getJSON('content/json/recent.json', function(data) {
	    $.get('assets/mustache/recent.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.recent').html(html);
	    });

	});

	<!--
	Mustache - homepage user - console template -->
	$.getJSON('content/json/user-console.json', function(data) {
	    $.get('assets/mustache/user-console.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.user-console').html(html);
	    });
	});

	<!--
	Mustache - homepage user - topic template -->
	$.getJSON('content/json/user-topic.json', function(data) {
	    $.get('assets/mustache/user-topic.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.user-topic').html(html);
	    });
	});

	<!--
	Mustache - homepage topic - spotlight template -->
	$.getJSON('content/json/topic-spotlight.json', function(data) {
	    $.get('assets/mustache/topic-spotlight.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.topic-spotlight').html(html);
	    });
	});
</script>
</body>

</html>